Table 4.
Comparison Between Patients Treated With Tigecycline Monotherapy and Non-Tigecycline Monotherapya
| Variables | Tigecycline Monotherapy (n = 11) |
Non-Tigecycline Monotherapy (n = 44) |
P |
| Demographics | |||
| Age, years, median (IQR) | 67 (56–77) | 72 (63–77.75) | .335 |
| Male sex | 8 (72.7) | 26 (59.1) | .405 |
| Nosocomial-acquired infection | 11 (100) | 43 (97.7) | 1.000 |
| Healthcare-associated infection | 0 (0.0) | 1 (2.3) | 1.000 |
| ICU-acquired isolate | 4 (36.4) | 23 (52.3) | .345 |
| Previous hospitalizationb | 4 (36.4) | 24 (54.5) | .281 |
| Microbiology | |||
| Klebsiella pneumoniae | 9 (81.8) | 35 (79.5) | .866 |
| Escherichia coli | 2 (18.2) | 9 (20.5) | .866 |
| Carbapenemase-producing strains | 3 (27.3) | 13 (29.5) | .882 |
| Clinical Syndrome | |||
| Pneumonia | 5 (45.5) | 11 (25.0) | .182 |
| Urinary tract infection | 0 (0.0) | 2 (4.5) | 1.000 |
| Intra-abdominal infection | 3 (27.3) | 13 (29.5) | .882 |
| Catheter-associated infection | 0 (0.0) | 5 (11.4) | .571 |
| Skin and soft tissue infection | 0 (0.0) | 2 (4.5) | 1.000 |
| Primary bacteremia | 3 (27.3) | 11 (25.0) | .877 |
| Comorbidities | |||
| Diabetes mellitus | 3 (27.3) | 13 (29.5) | .882 |
| Chronic obstructive pulmonary disease | 2 (18.2) | 3 (6.8) | .259 |
| Chronic respiratory failure with mechanical ventilator | 2 (18.2) | 11 (25.0) | .634 |
| Congestive heart failure | 2 (18.2) | 7 (15.9) | .855 |
| Cerebrovascular disease | 5 (45.5) | 5 (11.4) | .009 |
| Chronic kidney diseasec | 4 (36.4) | 13 (29.5) | .662 |
| Liver cirrhosis | 1 (9.1) | 6 (13.6) | .686 |
| Malignancy | 3 (27.3) | 19 (43.2) | .335 |
| Immunocompromised stated | 3 (27.3) | 8 (18.2) | .500 |
| Previous surgerye | 4 (36.4) | 19 (43.2) | .682 |
| Charlson Comorbidity Index, median (IQR) | 6 (3–12) | 7 (3–9) | .135 |
| Invasive Procedures 7 Days Preceding Onset of Infection | |||
| Indwelled central venous catheter | 6 (54.5) | 24 (54.5) | 1.000 |
| Indwelled urinary catheter | 6 (54.5) | 23 (52.3) | .893 |
| Surgical drainage | 3 (27.3) | 9 (20.5) | .624 |
| Mechanically ventilated | 3 (27.3) | 22 (50.0) | .176 |
| Renal replacement therapy | 4 (36.4) | 9 (20.5) | .267 |
| Severity of Illness | |||
| Septic shock | 2 (18.2) | 8 (18.2) | 1.000 |
| APACHE II score, median (IQR) | 22 (17–30) | 25.5 (16.25–28.75) | .758 |
| 14-day mortality | 2 (18.2) | 15 (34.1) | .307 |
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range.
aData are expressed as number (%) unless specified otherwise.
bWithin 3 months preceding onset of infection.
cChronic kidney disease stage 4 and stage 5.
dUse of steroid dose equivalent to ≥20 mg of prednisolone or immunosuppressants 30 days preceding onset of infection, patients as transplantation recipient, or patients with HIV infection.
eWithin 30 days preceding onset of infection.